Assessment of tissue factor pathway inhibitor 2 (<scp>TFPI2</scp>) as a novel serum marker for malignant tumors of the ovary before and after treatment: A case‐control study
Our results suggest the clinical validity of TFPI2 as a serum tumor marker for postoperative recurrence screening among malignant ovarian tumors.
Authors
- Yuki Yamada (ORCID: https://orcid.org/0000-0003-2113-5329)
- Hiroshi Kobayashi (ORCID: https://orcid.org/0000-0002-8124-6269)
- Taichi Mizushima (ORCID: https://orcid.org/0000-0002-3505-4717)
- Noriaki Arakawa (ORCID: https://orcid.org/0000-0003-2286-0629)
- Kentaro Sakamaki (ORCID: https://orcid.org/0000-0002-4443-9993)
- Fuminori Kimura (ORCID: https://orcid.org/0000-0002-9840-4227)
- Kazumi Kubota (ORCID: https://orcid.org/0000-0003-2270-2313)
- Naho Yokota
- Etsuko Miyagi (ORCID: https://orcid.org/0000-0002-5492-0844)
- Yuki Ogawara
- Etsuko Yamazaki
Institutions
- Juntendo University (JP)
- Yokohama City University Hospital (JP)
- University of Tokyo Hospital (JP)
- Yokohama Rosai Hospital (JP)
- National Institute of Health Sciences (JP)
- Nara Medical University (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- Journal of obstetrics and gynaecology research
- Published
- 2025-02-01
- DOI
- https://doi.org/10.1111/jog.16241
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00